Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beat
BioSpace
Despite the continued decline of Pfizer's COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.
pharminent
May 5, 2026 (Last updated: May 5, 2026)
BioSpace
Despite the continued decline of Pfizer’s COVID-19 products, shares stayed stable on Tuesday morning after the New York pharma reported a first quarter beat, which was led by Eliquis and Ibrance.
